Search Results - "Serve, H."

Ubiquitination and selective autophagy by Shaid, S, Brandts, C H, Serve, H, Dikic, I

“…Ubiquitination has long been recognised as a key determinator of protein fate by tagging proteins for proteasomal degradation. Most recently, the ability of…”
Get full text

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia by Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, Ottmann, O G

“…Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib…”
Get full text

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry by Kaifie, A, Kirschner, M, Wolf, D, Maintz, C, Hänel, M, Gattermann, N, Gökkurt, E, Platzbecker, U, Hollburg, W, Göthert, J R, Parmentier, S, Lang, F, Hansen, R, Isfort, S, Schmitt, K, Jost, E, Serve, H, Ehninger, G, Berdel, W E, Brümmendorf, T H, Koschmieder, S

“…Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF),…”
Get full text

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) by Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H, Ottmann, O G

Get full text

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 by Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., Dongen, J. J. M. van, Ottmann, O. G.

“…Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment…”
Get full text

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center by Zeller, T., Muenstedt, K., Stoll, C., Schweder, J., Senf, B., Ruckhaeberle, E., Becker, S., Serve, H., Huebner, J.

“…Purpose About 40–50 % of cancer patients use complementary and alternative medicine (CAM). Women, and especially those with gynecological cancers, are more…”
Get full text

Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape by Silva, P, Neumann, M, Schroeder, M P, Vosberg, S, Schlee, C, Isaakidis, K, Ortiz-Tanchez, J, Fransecky, L R, Hartung, T, Türkmen, S, Graf, A, Krebs, S, Blum, H, Müller-Tidow, C, Thiede, C, Ehninger, G, Serve, H, Hecht, J, Berdel, W E, Greif, P A, Röllig, C, Baldus, C D

Get full text

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells by Jayavelu, A K, Müller, J P, Bauer, R, Böhmer, S-A, Lässig, J, Cerny-Reiterer, S, Sperr, W R, Valent, P, Maurer, B, Moriggl, R, Schröder, K, Shah, A M, Fischer, M, Scholl, S, Barth, J, Oellerich, T, Berg, T, Serve, H, Frey, S, Fischer, T, Heidel, F H, Böhmer, F-D

“…Activating mutations of FMS -like tyrosine kinase 3 (FLT3), notably internal tandem duplications (ITDs), are associated with a grave prognosis in acute myeloid…”
Get full text

Karyotype complexity and prognosis in acute myeloid leukemia by Stölzel, F, Mohr, B, Kramer, M, Oelschlägel, U, Bochtler, T, Berdel, W E, Kaufmann, M, Baldus, C D, Schäfer-Eckart, K, Stuhlmann, R, Einsele, H, Krause, S W, Serve, H, Hänel, M, Herbst, R, Neubauer, A, Sohlbach, K, Mayer, J, Middeke, J M, Platzbecker, U, Schaich, M, Krämer, A, Röllig, C, Schetelig, J, Bornhäuser, M, Ehninger, G

“…A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid…”
Get full text

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients by Röllig, C., Kramer, M., Gabrecht, M., Hänel, M., Herbst, R., Kaiser, U., Schmitz, N., Kullmer, J., Fetscher, S., Link, H., Mantovani-Löffler, L., Krümpelmann, U., Neuhaus, T., Heits, F., Einsele, H., Ritter, B., Bornhäuser, M., Schetelig, J., Thiede, C., Mohr, B., Schaich, M., Platzbecker, U., Schäfer-Eckart, K., Krämer, A., Berdel, W.E., Serve, H., Ehninger, G., Schuler, U.S.

“…The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients…”
Get full text

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG by Lengfelder, E, Haferlach, C, Saussele, S, Haferlach, T, Schultheis, B, Schnittger, S, Ludwig, W-D, Staib, P, Aul, C, Grüneisen, A, Kern, W, Reichle, A, Serve, H, Berdel, W E, Braess, J, Spiekermann, K, Wörmann, B, Sauerland, M-C, Heinecke, A, Hiddemann, W, Hehlmann, R, Büchner, T

“…The objective of this study for newly diagnosed acute promyelocytic Leukemia (APL) was to evaluate the efficacy of an intensified double induction chemotherapy…”
Get full text

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia by Müller-Tidow, C, Tschanter, P, Röllig, C, Thiede, C, Koschmieder, A, Stelljes, M, Koschmieder, S, Dugas, M, Gerss, J, Butterfaß-Bahloul, T, Wagner, R, Eveslage, M, Thiem, U, Krause, S W, Kaiser, U, Kunzmann, V, Steffen, B, Noppeney, R, Herr, W, Baldus, C D, Schmitz, N, Götze, K, Reichle, A, Kaufmann, M, Neubauer, A, Schäfer-Eckart, K, Hänel, M, Peceny, R, Frickhofen, N, Kiehl, M, Giagounidis, A, Görner, M, Repp, R, Link, H, Kiani, A, Naumann, R, Brümmendorf, T H, Serve, H, Ehninger, G, Berdel, W E, Krug, U

“…DNA methylation changes are a constant feature of acute myeloid leukemia. Hypomethylating drugs such as azacitidine are active in acute myeloid leukemia (AML)…”
Get full text

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations by Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, O G, Rieger, M A

Get full text

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia by Krug, U, Berdel, W E, Gale, R P, Haferlach, C, Schnittger, S, Müller-Tidow, C, Braess, J, Spiekermann, K, Staib, P, Beelen, D, Serve, H, Schliemann, C, Stelljes, M, Balleisen, L, Maschmeyer, G, Grüneisen, A, Eimermacher, H, Giagounidis, A, Rasche, H, Hehlmann, R, Lengfelder, E, Thiel, E, Reichle, A, Aul, C, Ludwig, W-D, Kern, W, Haferlach, T, Köpcke, W, Görlich, D, Sauerland, M C, Heinecke, A, Wörmann, B J, Hiddemann, W, Büchner, T

“…We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive…”
Get full text

Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients by Gueller, S., Duenzinger, U., Wolf, T., Ajib, S., Mousset, S., Berger, A., Martin, H., Serve, H., Bug, G.

“…Introduction Respiratory syncytial virus (RSV) is a frequent cause of respiratory tract infectious disease (RTID) in allogeneic hematopoietic stem cell…”
Get full text

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia by Pfeifer, H, Lange, T, Wystub, S, Wassmann, B, Maier, J, Binckebanck, A, Giagounidis, A, Stelljes, M, Schmalzing, M, Dührsen, U, Wunderle, L, Serve, H, Brück, P, Schmidt, A, Hoelzer, D, Ottmann, O G

“…Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine…”
Get full text

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations by Heidrich, K, Thiede, C, Schäfer-Eckart, K, Schmitz, N, Aulitzky, W E, Krämer, A, Rösler, W, Hänel, M, Einsele, H, Baldus, C D, Trappe, R U, Stölzel, F, Middeke, J M, Röllig, C, Taube, F, Kramer, M, Serve, H, Berdel, W E, Ehninger, G, Bornhäuser, M, Schetelig, J

“…The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute…”
Get full text

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial by Schetelig, J, Schaich, M, Schäfer-Eckart, K, Hänel, M, Aulitzky, W E, Einsele, H, Schmitz, N, Rösler, W, Stelljes, M, Baldus, C D, Ho, A D, Neubauer, A, Serve, H, Mayer, J, Berdel, W E, Mohr, B, Oelschlägel, U, Parmentier, S, Röllig, C, Kramer, M, Platzbecker, U, Illmer, T, Thiede, C, Bornhäuser, M, Ehninger, G

“…The optimal timing of allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) is controversial. We report on 1179 patients…”
Get full text

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib by Schaab, C, Oppermann, F S, Klammer, M, Pfeifer, H, Tebbe, A, Oellerich, T, Krauter, J, Levis, M, Perl, A E, Daub, H, Steffen, B, Godl, K, Serve, H

Get full text

Role of receptor tyrosine kinases in gastric cancer： New targets for a selective therapy by Becker, J C, Muller-Tidow, C, Serve, H, Domschke, W, Pohle, T

“…Receptor tyrosine kinases （RTKs） such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation…”
Get full text